A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
BeOne Medicines
Hoffmann-La Roche
Lumos Pharma
Novartis
Eisai Inc.
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
BeOne Medicines
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Beijing Wehand-Bio Pharmaceutical Co., Ltd
Astellas Pharma Inc
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Hoffmann-La Roche
AbbVie
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hutchmed
Hoffmann-La Roche
Hoffmann-La Roche
Adlai Nortye Biopharma Co., Ltd.
Incyte Corporation
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Genfleet Therapeutics (Shanghai) Inc.
Merck Sharp & Dohme LLC
BeiGene
Hoffmann-La Roche
Jiangsu Simcere Pharmaceutical Co., Ltd.
Laekna Limited
AbbVie
BeiGene
Merck Sharp & Dohme LLC
Incyte Corporation
Leap Therapeutics, Inc.
Gilead Sciences
American Regent, Inc.
ALX Oncology Inc.
Leap Therapeutics, Inc.
BeiGene
Tesaro, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC